As on: Oct 13, 2025 11:58 PM
To,
The Members
Bajaj Healthcare Limited
Your Directors are pleased to present their 32nd Report on the business and operations of the Company along with the Audited Financial Statements for the financial year ended 31st March 2025.
SUMMARY OF THE FINANCIAL PERFORMANCE OF THE COMPANY:
The Company's financial performance for the year ended 31st March 2025 as compared to the previous financial year is summarized below:
(Rs. in Lakhs)
Particulars
During the year under review, the Gross Income was '56,200.68/- lakhs which is 16.57% more than previous year's income of Rs. 48,210.42/- lakhs. The net profit after tax during the year from continued operations was Rs. 4,292.88 lakhs as compared to previous year's losses of Rs. 8,656.87/- lakhs.
REVIEW OF COMPANY'S OPERATIONS:
The Company is engaged in the business of manufacturing and exporting of allied activities of manufacturing Active Pharmaceuticals Ingredients and Formulations.
For further details on the Company's performance, operations and strategies for growth, please refer to the Management Discussion and Analysis section which forms a part of this Annual Report.
There was no change in nature of the business of the Company.
DIVIDEND:
The Board of Directors at their meeting held on 26th May 2025, has recommended payment of Rs. 1.00/- (Rupee One Only) (20%) as Final Dividend per equity share of the face value of Rs. 5/- (Rupees Five only) each, for the financial year ended 31st March 2025. The payment of Final Dividend is subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM) of the Company.
The dividend recommended is in accordance with the Dividend Distribution Policy of the Company. The Dividend Distribution Policy, in terms of Regulation 43A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") is available on the Company's website at https://www.baiaihealth.com/wp-content/ uploads/2022/07/Dividend-Distribution-Policy.pdf .
In terms of the provisions of the Income-tax Act, 1961, dividends paid or distributed by the Company shall be taxable in the hands of the Shareholders. The Company shall, accordingly, make the payment of the final dividend for the year ended 31st March 2025 after deduction of tax at source.
DEPOSITS:
The Company has not accepted nor renewed any deposits from the public during the year under review and as such, there are no outstanding deposits within the meaning of Section 73 of the Companies Act, 2013 and the Companies (Acceptance of Deposits) Rules, 2014.
PARTICULARS OF LOANS, GUARANTEE AND INVESTMENTS:
Details of loans, guarantees and investments under the provisions of Section 186 of the Act read with the Companies (Meetings of Board and its Powers) Rules, 2014, as on 31st March 2025, have been disclosed in the Financial Statements of the Company.
TRANSFER TO RESERVES IN TERMS OF SECTION 134(3) (j) OF THE COMPANIES ACT, 2013:
The Company has not transferred any amount to General Reserves for the financial year 2024-25.
TRANSFER OF UNPAID AND UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND ("IEPF"):
Pursuant to the provisions of Section 124 of the Act and Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 (IEPF Rules), the declared dividends, which remain unpaid or unclaimed for a period of 7 (seven) years from the date of its transfer to unpaid/unclaimed dividend account are required to be transferred by the Company to Investor Education and Protection Fund (IEPF). Details of unpaid/unclaimed dividend are a part of the Report on Corporate Governance that forms part of this Annual Report.
MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY WHICH HAVE OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR TO WHICH THE FINANCIAL STATEMENT RELATES AND THE DATE OF THE REPORT: There have been no material changes or commitments affecting the financial position of the Company between the end of the financial year and the date of this report.
INFORMATION ABOUT SUBSIDIARY/ JV/ ASSOCIATE COMPANY:
The Company has no Subsidiary, Joint venture or Associate Company.
In April 2025, the Company acquired Genrx Pharmaceuticals Private Limited (in Liquidation) ("Genrx"), a Corporate Debtor, on a going concern basis. Genrx is an existing company incorporated under the provisions of the Companies Act, 1956. The acquisition was made for a total consideration of '10,85,00,000 (Rupees Ten Crores Eighty-Five Lakhs only).
Subsequently, on 3rd June 2025, the Company filed an application with the Hon'ble National Company Law Tribunal (NCLT), Mumbai, seeking certain reliefs and concessions necessary for the effective implementation of the acquisition and takeover of Genrx as a going concern.
SHARE CAPITAL:
Paid-up Share Capital:
As on 31st March 2025, the Paid-up Equity Share Capital of the Company stood at '15,79,16,260, divided into 3,15,83,252 equity shares of face value Rs. 5/- each.
During the financial year, the Company undertook the following capital-related activities on 19th September 2024:
I ssued and allotted 39,84,852 (Thirty-Nine Lakhs Eighty-Four Thousand Eight Hundred and Fifty-Two) equity shares of face value Rs. 5/- (Rupees Five Only) each at an issue price of Rs. 338/- (Rupees Three Hundred Thirty-Eight Only) including a share premium of Rs. 333/- (Rupees Three Hundred Thirty-Three Only) per share on a preferential basis to persons belonging to the Non-Promoter Category, aggregating to Rs. 134,68,79,976/- (Rupees One Hundred and Thirty-Four Crores Sixty-Eight Lakhs Seventy-Nine Thousand Nine Hundred and Seventy-Six Only).
Issued and allotted 20,79,409 (Twenty Lakhs Seventy-Nine Thousand Four Hundred and Nine) Convertible Warrants of Rs. 5/- (Rupees Five Only) each at an issue price of Rs. 338/- (Rupees Three Hundred Thirty-Eight Only) including a share premium of Rs. 333/- per warrant on a preferential basis to Promoters and certain identified Non-Promoter persons/entities, aggregating to Rs. 70,28,40,242/- (Rupees Seventy Crores Twenty-Eight Lakhs Forty Thousand Two Hundred and Forty-Two Only). The Company received 25% of the subscription amount at the time of allotment, while the remaining 75% is uncalled and will be payable within 18 months from the date of allotment, i.e., by 19th March 2026.
In compliance with Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company appointed CARE Ratings Limited as the Monitoring Agency to oversee the utilization of proceeds from the preferential issue. The Company has submitted the Monitoring Agency Report to the Stock Exchanges as required.
Further, during the year, the shareholders approved the 'Bajaj Healthcare Limited Employee Stock Option Scheme 2024' ("Scheme") at the Annual General Meeting of the Company held on 30th September 2024. Under this scheme, the Company is authorized to grant up to 14,00,000 stock options to eligible employees of the Company, in one or more tranches.
During the year under review, the Company has not bought back any of its securities nor issued any shares with differential rights, sweat equity shares and options under Employees Stock Option Scheme.
TRADING OF COMPANY'S EQUITY SHARES ON STOCK EXCHANGE:
The Company's equity shares were actively traded on BSE Limited and National Stock Exchange of India Limited and were not suspended during the year under review.
CREDIT RATING:
India Ratings and Research (Ind-Ra) has revised the rating outlook from IND A-/ Negative to IND A-/Stable on 15th May 2025.
MATTERS RELATED TO DIRECTORS AND KEY MANAGERIAL PERSONNEL:
The Board has an optimum combination of Executive and Non-Executive Directors and is headed by an Executive Chairman, Mr. Sajankumar Rameshwarlal Bajaj. The Board of the Company is diverse in terms of qualification, competence, skills and expertise which enables it to ensure long-term value creation for all the stakeholders.
Following changes have taken place in the Board of Directors during the year under review:
Appointment of Mr. Yaqoob Ali:
Based on the recommendation of the Nomination and Remuneration Committee (NRC) and subject to the approval of the shareholders, the Board, in accordance with the provisions of Section 149 read with Schedule IV to the Act and applicable SEBI Listing Regulations, appointed Mr. Yaqoob Ali (DIN: 07655705) as an Independent Director of the Company, not liable to retire by rotation, for a term of five consecutive years commencing from 14th August 2024. The shareholders of the Company approved the appointment of Mr. Yaqoob Ali as an Independent Director of the Company by way of a Special Resolution in the Annual General Meeting was held on 30th September 2024, for the abovementioned tenure.
Cessation of Mr. Loukik Tipnis
Mr. Loukik Tipnis (DIN: 08188583) completed his tenure of five consecutive years as an Independent Director of the Company w.e.f. close of the business hours of 30th September 2024 upon completion of his second term.
Appointment/Re-appointments of Directors in AGM
Director retiring by rotation:
In accordance with the provisions of Section 152 of the Act and the Articles of Association of the Company, Ms. Namrata S. Bajaj (DIN: 05327071), Whole-Time Director is liable to retire by rotation at the ensuing Annual General Meeting (AGM) and being eligible, offers herself for re-appointment. The Board recommends her reappointment.
Key Managerial Personnel
During the financial year ended 31st March 2025, the following changes were made in Key Managerial Personnel of the Company, on the recommendation of the Nomination and Remuneration Committee ("NRC"):
Appointment
(a) Ms. Monica Tanwar was appointed as a Company Secretary and Compliance Officer of the Company w.e.f. 11th February 2025.
Cessation
(a) Ms. Apurva Bandivadekar, Company Secretary & Compliance Officer of the Company, resigned w.e.f. 31st January 2025.
The Board of the Company, based on the recommendation of Nomination and Remuneration Committee through a resolution passed by Circulation dated 27th June 2025, has considered and approved the re-appointment of Ms. Kejal Niken Shah as NonExecutive Independent Director of the Company for a second term of five consecutive years with effect from 30th June 2025 to 29th June 2030 subject to the approval of Members at the ensuing AGM of the Company.
As stipulated under the Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, details of all the Directors proposed to be appointed/re-appointed is given in the Annexure A to the Notice of the 32nd Annual General Meeting.
INDEPENDENT DIRECTOR(S):
The Company has, inter alia, received the following declarations from all the Independent Directors confirming that:
they meet the criteria of independence as prescribed under the provisions of the Act, read with the Schedule and Rules issued thereunder, and the Listing Regulations. There has been no change in the circumstances affecting their status as Independent Directors of the Company;
they have complied with the Code for Independent Directors prescribed under Schedule IV to the Act; and
they have registered themselves with the Independent Director's Database maintained by the Indian Institute of Corporate Affairs.
None of the Directors of the Company are disqualified for being appointed as Directors as specified in Section 164(2) of the Act and Rule 14(1) of the Companies (Appointment and Qualification of Directors) Rules, 2014. The terms and conditions of appointment of Independent Directors are disclosed on the website of the Company at https://www.baiaihealth.com/wp-content/uploads/2020/05/ Terms-and-conditions-of-Appt-of-Independent-Director.pdf
In the opinion of the Board, the Independent Directors of the Company fulfil the conditions specified under the Act and Listing Regulations and are independent of the management.
NUMBER OF MEETINGS OF THE BOARD:
During the year, the Board convened and held seven (7) meetings. The interval between any two consecutive meetings was within the period prescribed under the Companies Act and applicable Secretarial Standards. Detailed information regarding the Board meetings is provided in the Report on Corporate Governance, which forms an integral part of this Annual Report.
PERFORMANCE EVALUATION OF THE BOARD:
In compliance with the provisions of the Companies Act, 2013 and Regulation 19 read with Part D of Schedule II of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), the Board of Directors has carried out the annual performance evaluation for the financial year 2024-25.
The performance evaluation of the Chairman, non-independent Directors and Board as a whole was also carried out by the Independent Directors at their separate meeting held as on 28th February 2025 inter alia:
To evaluate the performance of non-independent directors and the Board as a whole;
To evaluate performance of the Chairman and Managing Director of the Company; and
To evaluate the quality, quantity and timelines of flow of information between the executive management and the Board.
A structured questionnaire was used to facilitate the evaluation process, covering various aspects such as the adequacy of the Board's and Committees' composition, Board culture and dynamics, execution of duties, fulfillment of obligations, and adherence to corporate governance practices.
The suggestions made at the meeting of the Independent Directors were communicated to the Board, Chairman and the Executive Directors for taking appropriate steps. The majority of Independent Directors were present at the meeting. The Directors expressed their satisfaction with the evaluation process.
COMMITTEES OF THE BOARD:
With a view to have a more focused attention on various facets of business and for better accountability, the Board has constituted a set of Committees in accordance with the requirements of the Act and Listing Regulations. The Board supervises the execution of its responsibilities by the Committees and is responsible for their action. The statutorily mandated Committees constituted under the provisions of the Act and Listing Regulations are Audit Committee, Nomination and Remuneration Committee, Corporate Social Responsibility (CSR) Committee, Stakeholders' Relationship Committee and Risk Management Committee.
A detailed note on the composition of the Committees, terms of reference and other such details of these Committees are provided in the Report on Corporate Governance forming part of this Annual Report. During the year under review, the Board has accepted all the recommendations of the Audit Committee and of all other Committees of the Board.
FAMILIARIZATION PROGRAM FOR INDEPENDENT DIRECTORS:
All Independent Directors are familiarized with the operations and functioning of the Company. The details of the training and familiarization program are provided in the Corporate Governance Report and are also available on the website of the Company at https://www.baiaihealth.com/wp-content/uploads/2025/07/ Familiarization-Programmes-FY-2025.pdf
NOMINATION AND REMUNERATION POLICY:
Pursuant to the provisions of Section 178 of the Act and Regulation 19 of Listing Regulations and on recommendation of the Nomination and Remuneration Committee, the Board of Directors has adopted a policy on Criteria for Selection and Appointment of Directors, Senior Management Personnel and their remuneration. Nomination and Remuneration policy is applicable to all Directors, Key Managerial Personnel (KMP), Senior Management team and other employees of the Company. The Nomination and Remuneration Policy of the Company has been uploaded on the Company's website at https://www.baiaihealth.com/wp-content/ uploads/2020/05/REMUNERATION-POLICY.pdf
VIGIL MECHANISM / WHISTLE BLOWER POLICY:
As per the provisions of Section 177(9) and (10) of the Act, the Company has adopted a Whistle Blower Policy for establishing vigil mechanism for the Employees and Directors to report genuine concerns, unethical behavior and irregularities, if any noticed by them to the Chairman of the Audit Committee in the Company which can adversely affects Company's operations. The same is reviewed by the Audit Committee from time to time. No concerns or irregularities have been reported by Employees/ Directors to date. The said policy is available on the Company's website https:// www.baiaihealth.com/wp-content/uploads/2020/05/whistle- blower-policy.pdf
INSIDER TRADING CODE
The Company has adopted a 'Code of Conduct to regulate, monitor and report trading by designated persons in Listed or Proposed to be Listed Securities' ("the Code") in accordance with the requirements of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (PIT Regulations). This Code is displayed on the Company's website. The obiect of the PIT Regulations is to curb the practice of insider trading in the securities of a listed Company. The Code is applicable to Promoters and Promoter's Group, all Directors and such Designated Employees who are expected to have access to unpublished price sensitive information relating to the Company. The Code is available on the Company's website at https://www.baiaihealth.com/wp-content/ uploads/2021/06/CODE-FOR-UPSI.pdf .
The Company Secretary appointed serves as the Compliance Officer to ensure compliance and effective implementation of the Insider Trading Code. Matters related to the insider trading code are reported to the Audit Committee.
BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORTING:
The Business Responsibility and Sustainability Report of the Company for the year ended 31st March 2025, forms part of the Annual Report and is also made available on the website of the Company at https://www.baiaihealth.com/wp-content/ uploads/2025/08/BRSR-2025.pdf.
RISK MANAGEMENT:
Risk management is integral to our Company's strategic framework and is essential for achieving our long-term objectives. Our success depends on our ability to proactively identify and leverage opportunities while effectively managing associated risks.
The Board of Directors has entrusted the Risk Management Committee with the responsibility of overseeing the Company's risk management framework. This includes ensuring that key risks are identified, assessed, and maintained within acceptable limits. Mitigation plans for significant risks are seamlessly integrated into both functional and business plans and are reviewed regularly by the Senior Leadership Team.
Our risk management approach is designed to provide reasonable assurance that:
The Company's assets are safeguarded,
Business risks are continuously identified, assessed, and mitigated,
Relevant and material information is reported appropriately to Senior Management, including the Chairman & Managing Director, Chief Financial Officer, Audit Committee, and the Board.
The Board has approved a comprehensive Risk Management Policy, which outlines our structured approach to risk governance. The said policy is available on the Company's website https://www. baiaihealth.com/wp-content/uploads/2023/05/Risk-Management- Policy-1.pdf
STATEMENT IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS:
The Company has established an adequate internal control system that is commensurate with the nature of its business, as well as the size and complexity of its operations. These internal control systems have been functioning effectively and continue to support the organization in maintaining operational excellence and regulatory compliance.
The internal control framework comprises well-documented policies and procedures designed to:
Ensure the reliability and integrity of financial reporting,
Provide timely feedback on the achievement of operational and strategic goals,
Ensure compliance with applicable laws, regulations, internal policies, and procedures, and
Safeguard the Company's assets and resources by ensuring they are acquired economically, used efficiently, and adequately protected.
The Company also has in place an adequate Internal Financial Controls (IFC) system relating to financial reporting. This system ensures that all financial transactions are appropriately authorized, accurately recorded, and reported in a timely manner. The Internal Financial Controls framework provides reasonable assurance regarding the authenticity and integrity of the Company's financial statements.
AUDITORS AND THEIR REPORT Statutory Audit:
At the 30th Annual General Meeting of the Company held on 30th September 2023, the members have approved the appointment of M/s. Walker Chandiok & Co. LLP, Chartered Accountants (Firm Registration No. 001076N/N500013) as the Statutory Auditors of the Company to hold office for a period of five consecutive years from the conclusion of 31st Annual General Meeting till the conclusion of 35th Annual General Meeting to be held in the year 2028.
The Auditor's Report for the financial year ended 31st March, 2025, does not contain any qualifications, adverse remark or reservation and therefore, do not call for any further explanation or comments from the Board under Section 134(3) of the Act. The Statutory Auditors have issued an unmodified opinion on the financial statements for the financial year 2024-25. The observations and comments given by the Auditors in their report read together with notes to Accounts are self-explanatory and hence do not call for any further comments under Section 134 of the Act.
Secretarial Audit:
SEBI vide notification no. SEBI/LAD-NRO/GN/2024/218 dated 12th December 2024 has introduced 'SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024' to establish detailed norms governing the appointment, reappointment, and removal of Secretarial Auditors in listed entities, effective from 31st December, 2024. The recent amendment mandates that the listed companies have to obtain shareholders' approval for appointment of Secretarial Auditors.
Accordingly, the Board of Directors of the Company has appointed Mr. Haresh Sanghvi, Practicing Company Secretary (M.No. 2259/ CoP: 3675), as the Secretarial Auditor of the Company for the period of 5 (five) consecutive years from Financial year 2025-26 till Financial year 2029-30 to carry out the audit of secretarial and related records of the Company subject to the approval of Shareholders in the ensuing Annual General Meeting of the Company.
The Company has received consent letter along with peer reviewed certificate from Mr. Haresh Sanghvi to act as the Secretarial Auditor for conducting an audit of the secretarial records of the Company for the period of 5 (five) consecutive years.
The Secretarial Audit Report pursuant to the provisions of Section 204 read with Section 134(3) of the Companies Act, 2013 was obtained from Mr. Haresh Sanghvi, Practicing Company Secretary in Form MR-3 for the financial year ended 31st March 2025, is enclosed with this report and marked as Annexure-I. The Secretarial Audit Report contains observation/ remark which is self-explanatory.
The Secretarial Compliance Report for the financial year ended 31st March 2025, issued by Mr. Haresh Sanghvi, in relation to compliance of all applicable SEBI Regulations/circulars/guidelines issued thereunder, pursuant to the requirement of Regulation 24A of the Listing Regulations, is enclosed with this report and marked as Annexure-II. The Secretarial Compliance Report has been voluntarily disclosed as part of the Annual Report as good disclosure practice.
Internal Audit & Controls:
The Board of Directors of the Company has appointed VJ Shah & Co., Chartered Accountants (FRN 109823W), as Internal Auditor of the Company for the financial year 2025-26 to carry out internal audit of the Company. They have carried out internal audit for the Financial Year 2024-25.
The findings and observations of the Internal Auditors are submitted to the Audit Committee at regular intervals. Based on these reports, the management takes appropriate corrective actions and implements the auditors' recommendations across relevant functions. This process contributes to the continuous strengthening of the internal control framework and enhances operational efficiency and compliance.
Cost Auditors:
In accordance with the provisions of Section 148 of the Companies Act, 2013, read with the Companies (Cost Records and Audit) Amendment Rules, 2014 as amended from time to time, the Company has maintained proper cost records as required under the Act and the Board of Directors, upon recommendation of the Audit Committee at their meeting held on 26th May 2025 appointed M/s. V. J. Talati & Co., Cost Accountants, as Cost Auditor of the Company for conducting the Cost Audit for the Financial year 2025-26 at a remuneration as mutually agreed between the Board & Cost Auditor. The said remuneration is subject to ratification by the members at the ensuing 32nd Annual General Meeting of the Company.
The Cost Audit Report for the financial year 2023-24 does not contain any qualification, reservation or adverse remark.
Reporting of fraud by Auditors:
During the year under review, there were no instances of fraud reported by the Statutory Auditors, Internal Auditor, Cost Auditor or the Secretarial Auditor to report to the Audit Committee and/ or the Board under Section 143(12) of Act and the rules framed thereunder.
PARTICULARS OF EMPLOYEES:
The statement of disclosure of Remuneration under Section197(12) of the Act read with the Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 ('Rules') is appended as Annexure III to this Report.
The information as per the provisions of Section 197(12) of the Act read with Rule 5(2) and 5(3) of the Rules is provided in a separate annexure forming part of this Report. However, the Annual Report is being sent to the Members of the Company excluding the said annexure. In terms of Section 136 of the Act, the said annexure is open for inspection at the Registered Office of your Company. Any Member interested in obtaining a copy of the said statement may write to the Company Secretary of the Company at investors@ bajajhealth.com .
COMPLIANCE WITH SECRETARIAL STANDARDS:
The Company has complied with the applicable mandatory Secretarial Standards issued by the Institute of Company Secretaries of India.
GENERAL DISCLOSURES:
ANNUAL RETURN:
The Annual Return as required under Section 92(3) read with Section 134(3)(a) of the Companies Act, 2013 ('the Act') in Form MGT-7 is available on the website of the Company at https://www . baiaihealth.com/wp-content/uploads/2025/08/MGT-7.pdf
RELATED PARTY TRANSACTIONS:
All related party transactions entered into during the financial year were conducted in the ordinary course of business and on an arm's length basis, in accordance with the provisions of the Companies Act, 2013. Accordingly, the provisions of Section 188 of the Act are not attracted.
There were no materially significant transactions with related parties that could have had a potential conflict with the interests of the Company. Hence, the disclosure of particulars in Form AOC-2 is not applicable.
The necessary disclosures as required under the Indian Accounting Standards (IND-AS) have been made in the notes to the Financial Statements forming part of this Annual Report.
The Company has adopted a Policy on Materiality of Related Party Transactions and on dealing with Related Party Transactions which is available on Company's website https://www.baiaihealth.com/ wp-content/uploads/2025/02/11.02.2025-BHL-Revised-RPT-Policy. pdf
DISCLOSURE UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:
The Company has always believed in providing a safe and harassment free workplace for every individual working on the Company's premises through various practices and always endeavors to provide an environment that is free from discrimination. All employees are treated with dignity with a view to maintain a work environment free of sexual harassment whether physical, verbal or psychological.
The Company has in place, Policy on Prevention, Prohibition and Redressal of Sexual Harassment for Women at Workplace in accordance with the requirements of Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.
The Company has also constituted an Internal Complaints Committee (ICC) to redress the complaints, if any, received regarding sexual harassment. All employees (permanent, contractual, temporary, trainees) are covered under this policy.
The Committee was re-constituted and approved by the Board in its meeting held on 11th February 2025.
The Committee comprises of:
Sr. Name of the No. Committee member(s)
Position in the Committee
Designation
1. Ms. Namrata S. Bajaj
Presiding Officer
Whole-Time Director
2. Mrs. Deepti Khasnis
Member
HR Executive
3. Mrs. Meghana Jagtap
Head Technical & Corporate Affairs
4. Mrs. Shilpa Bhagat
Senior Manager, Purchase
5. Mr. Ajay Singh
Legal Advisor
During the financial year under review, the Company has complied with the provisions relating to the constitution of Internal Complaints Committee under the Sexual Harrasment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. No complaint pertaining to sexual harassment were received during the financial year under review.
The following is a summary of sexual harassment complaints received and disposed of during the year:
(a) Number of complaints pending at the beginning of the year: Nil
(b) Number of complaints received during the year: Nil
(c) Number of complaints disposed off during the year: Nil
(d) Number of cases pending for more than 90 days: Nil
(e) Number of cases pending at the end of the year: Nil
SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS:
There are no significant and material orders passed by the Regulators, Courts or Tribunals during the financial year under review that would impact the going concern status of the Company and its future operations.
However, during the year, the Company received GST order from the Joint Commissioner, Vadodara-II, dated 25th October 2024. The order pertains to the Company claiming a refund of Input Tax Credit (ITC) on exports under Rule 89(4) of the CGST Rules, 2017, instead of Rule 89(4A)/(4B), under which the Company was otherwise eligible. The matter does not have a material impact on the financial statements or going concern assumption of the Company.
The Company has filed the writ petition against the aforementioned GST Order in the Hon'ble High Court of Gujarat.
MANAGEMENT DISCUSSION AND ANALYSIS REPORT :
Management Discussion and Analysis for the year under review is provided as separate section forming part of this Annual Report.
CORPORATE GOVERNANCE:
In compliance with the Regulation 34 read with Schedule V of the Listing Regulations, a detailed report on Corporate Governance is given as an Annexure IV and forms an integral part of this Annual Report. A Certificate from Mr. Haresh Sanghvi, Company Secretary in Practice confirming compliance of the conditions of Corporate Governance as stipulated under the SEBI Listing Regulations is appended to the Corporate Governance Report.
A Certificate of the CEO and CFO of the Company in terms of Regulation 17(8) of the Listing Regulations is also annexed.
DIRECTORS' RESPONSIBILITY STATEMENT:
Based on the framework ofInternal Financial Controls and compliance systems established and maintained by the Company, and the work performed by the Internal, Statutory, Cost and Secretarial Auditors including the Audit of Internal Financial Controls over financial reporting by the Statutory Auditors as well as the reviews undertaken by the Management and the relevant Board Committees, including the Audit Committee, the Board is of the opinion that the Company's Internal Financial Controls were adequate and operating effectively during the financial year 2024-25.
The Board of Directors acknowledge the responsibility for ensuring compliance with the provisions of Section 134(3)(c) read with Section 134(5) of the Act, in the preparation of annual accounts for the year ended on 31st March 2025 and confirm that:
a. in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
b. the directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company as at 31st March 2025 and of the profits of the Company for that period;
c. they have taken proper and sufficient care to the best of their knowledge and ability for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
d. t he annual accounts of the Company have prepared on a 'going concern' basis;
e. they have laid down Internal Financial Controls to be followed by the Company and that such Internal Financial Controls are adequate and were operating effectively; and
f. they have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.
CORPORATE SOCIAL RESPONSIBILITY:
During the financial year under review, the provisions requiring the Company to spend at least 2% of the average net profits of the three immediately preceding financial years on Corporate Social Responsibility (CSR) activities, in accordance with Section 135 of the Companies Act, 2013, were not applicable, as the Company incurred losses during the financial year 2023-24.
Notwithstanding the above, the Company voluntarily undertook CSR activities during the year, focusing primarily on projects in the area of Education, which is a notified activity under Schedule VII of the Companies Act, 2013, and aligned with the Company's CSR Policy.
The Report on CSR activities, as required under the Companies (Corporate Social Responsibility Policy) Rules, 2014, is annexed to this Report and marked as Annexure - V, forming an integral part of this Report.
ENERGY CONSERVATION, TECHNOLOGY ABSORPTION, RESEARCH & DEVELOPMENT AND FOREIGN EXCHANGE EARNINGS AND OUTGO:
The information on conservation of energy, technology absorption and foreign exchange earnings and outgo stipulated under section 134(3) (m) of the Act read with Rule 8(3) of the Companies (Accounts) Rules, 2014, are as follows:
I. Conservation of Energy
Steps taken on Energy Conservation -
Several initiatives have been successfully implemented to promote energy conservation:
a. Solar Power Initiative:
Implemented a solar power project under Power Purchase Agreements (PPA) with a capacity of upto 4.5 MW. This initiative is contributing to energy savings of approximately '1.6 crore per year.
b. Upgrade of Utility Pumps:
In the utility area, lower-efficiency pumps in the chilling plant were replaced with high-efficiency pumps and motors, resulting in significant energy savings.
c. Water Line Optimization:
General-use water lines were connected to the raw water line, replacing the RO water line, thereby reducing water treatment costs.
d. Replacement of Ejector Pumps:
Conventional vacuum water ejector pumps were replaced with graphite ejector pumps, leading to operational cost savings.
f. Expansion of R&D Facilities:
Plans are underway to expand R&D facilities further to focus on the development of advanced and asymmetric APIs.
g. Skilled Scientific Team:
A highly qualified team of organic and analytical chemists supports R&D activities, including documentation, validation of test results as per ICH guidelines, and preparation of high-quality technical packages and Drug Master Files (DMFs) for regulatory submissions.
Details of expenditure in R&D are as follows:
e. VFD Panel Installation:
A new Variable Frequency Drive (VFD) panel was installed in the 50TR brine plant, enhancing energy efficiency.
f. Air Supply Line Upgrade:
Instrument PU tube air supply lines were replaced with stainless steel (SS) lines to eliminate leakages and prevent air wastage, thus saving energy.
g. Oil Vacuum Pump Replacement:
Oil-based vacuum pumps were replaced with water ejector pumps, which offer lower maintenance and reduced energy and oil consumption.
II. Technology Absorption
a. Ascorbic Acid Technology Transfer:
Signed a Memorandum of Understanding (MoU) with ICT Mumbai for backward integration through technology transfer related to Ascorbic Acid production.
b. Peptide Synthesis Development:
Bajaj Healthcare is actively developing selective peptide molecules tailored to client requirements. The company is utilizing both solid and liquid phase peptide synthesis methods, scaling from milligram to gram levels in its new R&D laboratory. The lab is equipped with dedicated facilities for both synthesis and purification of peptides.
III. Research & Development
a. DSIR-Approved R&D Laboratory:
The R&D laboratory of Bajaj Healthcare Limited is recognized by the Department of Scientific and Industrial Research (DSIR), India.
b. Enhanced Research Facilities:
Advanced fume hoods, state-of-the-art equipment, and facilities have been installed to support synthetic research and scale-up activities for the development of new API process technologies under safe and controlled conditions.
c. Commercialization of Generic Molecules:
Several generic molecules under research have been successfully commercialized at the plant scale, utilizing environmentally friendly synthesis routes.
d. Novel Synthesis Routes:
R&D efforts are focused on developing novel, noninfringing synthesis routes for APIs, nutraceuticals, and related substances through commercially viable and eco-friendly processes.
e. Intellectual Property Development:
The company's R&D strength lies in creating IP assets by developing cost-effective and sustainable processes to address complex chemical synthesis challenges.
Nature of Expenditure
Recurring Expenditure
Capital Expenditure
Total i
IV. Foreign Exchange Earning and Outgo:
Earnings: Foreign Currency inflow amounting to Rs.12,047.82/- Lakhs
Outgo: Foreign Currency outgo amounting to Rs.11,471.76/- Lakhs
ENVIRONMENT AND POLLUTION CONTROL:
The Company remains fully committed to its responsibility towards a cleaner and greener environment. Our environmental management initiatives extend well beyond statutory compliance and are driven by a deep-rooted commitment to sustainable development.
In line with this philosophy, the Company continues to adopt and upgrade eco-friendly technologies across its operations as part of its growth and expansion programs, thereby ensuring harmony with nature.
During the year under review, the Company actively undertook afforestation initiatives, including the maintenance of a forest area and the plantation of 1347 number of trees and plants around its factory premises in the states of Gujarat and Maharashtra. These efforts reflect our ongoing dedication to environmental conservation and improving green cover in the regions where we operate.
STATUTORY COMPLIANCES:
The Company has complied with all applicable statutory and regulatory requirements during the year under review. A declaration confirming compliance with the provisions of Companies Act, 2013 & SEBI Regulations was placed by the Chief Financial Officer (CFO) at quarterly meetings of the Board of Directors.
The Company maintains a strong internal mechanism to ensure timely and effective compliance with the requirements of the Companies Act, 2013 & Securities and Exchange Board of India (SEBI) Regulations, and other applicable statutory authorities. This reflects the Company's commitment to sound governance practices and regulatory transparency.
THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER INSOLVENCY AND BANKRUPTCY CODE, 2016 (IBC, 2016) DURING THE YEAR:
During the financial year under review, the Company has not made any application under Insolvency and Bankruptcy Code 2016.
THE DETAILS OF DIFFERENCE BETWEEN AMOUNT OF VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM BANKS AND FINANCIAL INSTITUTIONS ALONG WITH REASONS THEREOF:
During the financial year under review, the Company has not entered into any One Time Settlement with Banks or Financial Institutions.
MATERNITY BENEFIT ACT, 1961:
The Company confirms its compliance with the applicable provisions of the Maternity Benefit Act 1961.
GENDER-WISE EMPLOYEE STRENGTH:
The Company has total gender wise employee strength as on 31st March 2025 as follows:
Sr. Particulars of Employees No.
ACKNOWLEDGEMENTS:
Your Directors would like to place on record their sincere gratitude to the various Central and State Government Departments, Organizations, and Agencies for their continued support and cooperation during the year.
The Directors also wish to place on record their heartfelt appreciation to all stakeholders of the Companyincluding customers, members, dealers, vendors, banks, and other business associatesfor their unwavering support and trust.
The Board further acknowledges and commends the commitment, dedication, and hard work demonstrated by all employees, which has been instrumental in the Company's achievements throughout the year.
A special note of thanks is extended to Mr. Sajankumar R. Bajaj, Chairman & Managing Director and to Mr. Anil Champalal Jain, Managing Directors of the Company for their visionary leadership and tireless efforts that have significantly contributed to the Company's sustained progress and growth.
For and on behalf of the Board of Directors of Bajaj Healthcare Limited
Sd/-
Anil Champalal Jain
Namrata Sajankumar Bajaj
Managing Director
Whole-Time director
DIN: 00226137
DIN: 05327071
Date: 28th July 2025
Place: Thane